Nuvectis Pharma (NVCT) Assets Average (2022 - 2026)

Nuvectis Pharma has disclosed Assets Average across 5 years of filings, most recently posting $28.6 million for Q1 2026.

• Assets Average for Q1 2026 came in at $28.6 million, up 17.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.6 million (up 17.13% YoY), and the FY2025 annual result was $25.2 million, up 33.14% from the prior year.
• Assets Average came in at $28.6 million for Q1 2026 at Nuvectis Pharma, down from $33.6 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $33.6 million in Q4 2025 to a low of $12.1 million in Q1 2022.
• The 5-year median for Assets Average is $20.6 million (2023), against an average of $22.0 million.
• Across the five-year window, Assets Average dropped 24.57% in 2024 and jumped 87.38% in 2025, its largest moves.
• Nuvectis Pharma's Assets Average stood at $22.6 million in 2022, then slipped by 8.45% to $20.7 million in 2023, then slipped by 13.35% to $18.0 million in 2024, then surged by 87.38% to $33.6 million in 2025, then declined by 15.14% to $28.6 million in 2026.
• The last three Assets Average figures came in at $28.6 million (Q1 2026), $33.6 million (Q4 2025), and $31.3 million (Q3 2025), per Business Quant data.